Myelofibrosis: Diagnosis and Therapy
Diagnosis
Diagnose myelofibrosis through bone marrow biopsy demonstrating fibrosis, combined with molecular testing for JAK2V617F, CALR, and MPL driver mutations, and if all are negative, search for high-risk mutations including ASXL1, EZH2, IDH1/IDH2, and SRSF2 1.
Diagnostic Workup
The diagnostic approach requires:
- Bone marrow examination: Aspirate and biopsy to assess degree of fibrosis and rule out other causes
- Driver mutation testing (present in ~90% of cases):
- JAK2V617F (most common)
- CALR mutations
- MPL mutations
- Complementary molecular markers when driver mutations are negative 1:
- ASXL1, EZH2, IDH1/IDH2, SRSF2 (prognostic significance)
- Complete blood count: Assess for anemia, thrombocytosis, or leukocytosis
- Peripheral blood smear: Look for leukoerythroblastosis, teardrop cells
- Cytogenetic analysis: Identify adverse cytogenetics
- Spleen assessment: Physical exam and imaging for splenomegaly
Key Diagnostic Pitfall
Pre-fibrotic primary myelofibrosis (pre-PMF) presents with isolated thrombocytosis and minimal fibrosis, easily confused with essential thrombocythemia. Overt fibrotic MF typically presents with anemia and splenomegaly at diagnosis 2.
Risk Stratification
Use MIPSS70+ v2.0 or DIPSS-plus scoring systems to stratify patients into low, intermediate-1, intermediate-2, or high-risk categories, as this determines treatment intensity 1, 2.
Risk factors include:
- Age
- Constitutional symptoms (fever, night sweats, weight loss)
- Hemoglobin level
- White blood cell count
- Peripheral blood blast percentage (>2% is adverse)
- Cytogenetic abnormalities
- High-risk mutations (ASXL1, EZH2, IDH1/IDH2, SRSF2)
- Transfusion dependence
Treatment Strategy
Low and Intermediate-1 Risk (Asymptomatic)
Observe asymptomatic low or intermediate-1 risk patients without initiating disease-modifying therapy 1.
- No evidence supports early intervention in asymptomatic disease
- Monitor every 3-6 months for disease progression
- Initiate treatment only when symptoms develop
Intermediate-2 and High-Risk Disease
Start ruxolitinib as first-line therapy for patients with intermediate-2 or high-risk myelofibrosis who have symptomatic splenomegaly 1.
Ruxolitinib Dosing and Monitoring
- Standard JAK1/JAK2 inhibitor, FDA and EMA approved
- Primary benefits: splenomegaly reduction and symptom improvement
- Moderate evidence for survival benefit (limited by small event numbers in trials) 1
- Critical limitation: Dose-limiting cytopenias are common 3
Intermediate-1 Risk with Symptoms
Use ruxolitinib for intermediate-1 risk patients only when highly symptomatic splenomegaly is present 1.
Alternative JAK Inhibitors
When ruxolitinib fails or is not tolerated:
Fedratinib (JAK2/FLT3 inhibitor):
- Approved in EU for second-line use
- Note: No longer available in Switzerland as of February 2025 2
Momelotinib (JAK1/JAK2 and ACVR1/ALK2 inhibitor):
- Preferred for patients with moderate to severe anemia or transfusion dependence 2, 4
- Approved in EU (any risk category) and Switzerland (intermediate/high-risk only)
- Particularly effective after prior ruxolitinib treatment
Pacritinib:
- Option for patients with severe thrombocytopenia 4
Allogeneic Stem Cell Transplantation
Recommend allogeneic stem cell transplantation for transplant-eligible patients with high or intermediate-2 risk disease, as this is the only potentially curative treatment 1, 2.
Transplant Indications for Intermediate-1 Risk
Also transplant intermediate-1 risk patients who are transplant-eligible and have ANY of the following 1:
- Refractory, transfusion-dependent anemia
- Peripheral blood blasts >2%
- Adverse cytogenetics
- High-risk mutations (ASXL1, EZH2, IDH1/IDH2, SRSF2)
Transplant Approach
- Perform in controlled setting
- Bridge with JAK inhibitor therapy before transplant 5
- Only curative option but limited by age, comorbidities, and procedure-related mortality 4
Symptom-Directed Palliative Therapy
For patients not candidates for intensive therapy, address specific problems:
Anemia Management
- Erythropoiesis-stimulating agents (if low erythropoietin levels)
- Androgens
- Immunomodulatory drugs
- Transfusion support
- Consider momelotinib if on JAK inhibitor therapy 2
Splenomegaly Without Systemic Therapy
- Splenectomy (high morbidity/mortality)
- Splenic radiation (temporary benefit)
Constitutional Symptoms
- JAK inhibitors provide significant benefit
- Assess symptom burden at baseline and monitor during treatment 6, 5
Treatment Sequencing After Ruxolitinib Failure
Switch to fedratinib, momelotinib, or pacritinib based on the patient's specific cytopenias and symptom profile 4:
- Anemia/transfusion dependence: Momelotinib preferred
- Thrombocytopenia: Pacritinib
- General ruxolitinib failure: Fedratinib or momelotinib
Consider clinical trial enrollment, as multiple novel agents and combination therapies are under investigation 7, 4.
Monitoring and Follow-Up
- Assess for thrombosis, bleeding, and cardiovascular risk factors
- Monitor for disease progression to acute leukemia (≥20% blasts defines AML) 8
- Repeat bone marrow biopsy if clinical deterioration suggests transformation
- Evaluate symptom burden regularly using validated tools 6, 5
Critical Practice Points
The evidence base for JAK inhibitors shows clear benefit for splenomegaly and symptoms, but survival benefit remains moderate quality evidence 1. Despite this limitation, JAK inhibitors represent standard of care for symptomatic intermediate-2 and high-risk disease based on consistent improvements in quality of life outcomes across multiple randomized trials 1.
The landscape is rapidly evolving with newer JAK inhibitors and combination approaches showing promise, but allogeneic transplantation remains the only proven curative strategy for eligible patients 2, 7.